NasdaqGM - Nasdaq Real Time Price USD

Kodiak Sciences Inc. (KOD)

Compare

9.32

+0.20

(+2.19%)

At close: January 6 at 4:00:01 PM EST

9.82

+0.50

(+5.42%)

After hours: 7:58:39 PM EST

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

Zacks 12 hours ago

KOD
+2.19%
VNDA

CTMX
Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership

Key Insights Significantly high institutional ownership implies Kodiak Sciences' stock price is sensitive to their...

Simply Wall St. 9 days ago

KOD
+2.19%
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Zacks 11 days ago

MNPR

ARQT

MSB.AX
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential

Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.

Zacks 27 days ago

KOD
+2.19%
PFE
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients. J

Benzinga 28 days ago

KOD
+2.19%
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks last month

KOD
+2.19%
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks last month

KOD
+2.19%
PFE

NVS
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024.

PR Newswire last month

KOD
+2.19%
Kodiak Sciences to Participate in Upcoming Investor Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. Members of the management team will also be available for one-on-one meetings.

PR Newswire last month

KOD
+2.19%
3 US Penny Stocks With Market Caps Under $500M To Consider

Major U.S. stock indices have recently slipped from record highs as investors brace for a wave of earnings reports, highlighting the market's ongoing volatility and uncertainty. Despite these fluctuations, penny stocks continue to present intriguing opportunities for investors looking to explore potential growth in smaller or newer companies. While the term "penny stock" might seem outdated, these investments can still offer significant upside when backed by strong financials and sound...

Simply Wall St. 2 months ago

KOD
+2.19%
TALK

TALKW
Kodiak Sciences to Present at Innovate Retina 2024

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.

PR Newswire 2 months ago

KOD
+2.19%
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.

Zacks 2 months ago

KOD
+2.19%
REGN
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be accessed virtually at https://edge.media-server.com/mmc/p/2ff5vrm7.

PR Newswire 3 months ago

KOD
+2.19%
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 3 months ago

KOD
+2.19%
Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET.

PR Newswire 3 months ago

KOD
+2.19%
Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 3 months ago

KOD
+2.19%
EXAS
Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks 4 months ago

KOD
+2.19%
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024.

PR Newswire 4 months ago

KOD
+2.19%
Kodiak Sciences Inc. (NASDAQ:KOD) is definitely on the radar of institutional investors who own 50% of the company

Key Insights Given the large stake in the stock by institutions, Kodiak Sciences' stock price might be vulnerable to...

Simply Wall St. 5 months ago

KOD
+2.19%
All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy

Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 5 months ago

KOD
+2.19%

Performance Overview

Return	KOD	S&P 500
YTD	-6.52%	+1.16%
1-Year	+209.63%	+27.21%
3-Year	-88.04%	+27.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kodiak Sciences Inc. (KOD)

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?

Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Kodiak Sciences to Participate in Upcoming Investor Conferences

3 US Penny Stocks With Market Caps Under $500M To Consider

Kodiak Sciences to Present at Innovate Retina 2024

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully

Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?

Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results

Kodiak Sciences Inc. (NASDAQ:KOD) is definitely on the radar of institutional investors who own 50% of the company

All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy

Performance Overview